178 related articles for article (PubMed ID: 33685300)
1. Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches.
Sahly NN; Banaganapalli B; Sahly AN; Aligiraigri AH; Nasser KK; Shinawi T; Mohammed A; Alamri AS; Bondagji N; Elango R; Shaik NA
Syst Biol Reprod Med; 2021 Jun; 67(3):209-220. PubMed ID: 33685300
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
[TBL] [Abstract][Full Text] [Related]
3. Identification of uterine leiomyosarcoma-associated hub genes and immune cell infiltration pattern using weighted co-expression network analysis and CIBERSORT algorithm.
Shen X; Yang Z; Feng S; Li Y
World J Surg Oncol; 2021 Jul; 19(1):223. PubMed ID: 34321013
[TBL] [Abstract][Full Text] [Related]
4. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
[TBL] [Abstract][Full Text] [Related]
5. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
[TBL] [Abstract][Full Text] [Related]
6. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
[TBL] [Abstract][Full Text] [Related]
7. Different characteristics of mitochondrial microsatellite instability between uterine leiomyomas and leiomyosarcomas.
Lee JH; Ryu TY; Cho CH; Kim DK
Pathol Oncol Res; 2011 Jun; 17(2):201-5. PubMed ID: 20853077
[TBL] [Abstract][Full Text] [Related]
8. Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma.
Yang Q; Falahati A; Khosh A; Mohammed H; Kang W; Corachán A; Bariani MV; Boyer TG; Al-Hendy A
Cells; 2022 Nov; 11(23):. PubMed ID: 36497061
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome.
Barlin JN; Zhou QC; Leitao MM; Bisogna M; Olvera N; Shih KK; Jacobsen A; Schultz N; Tap WD; Hensley ML; Schwartz GK; Boyd J; Qin LX; Levine DA
Neoplasia; 2015 Feb; 17(2):183-9. PubMed ID: 25748237
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis reveals candidate mRNA and their potential roles in uterine leiomyomas.
Xia L; Liu Y; Fu Y; Dongye S; Wang D
J Obstet Gynaecol Res; 2017 Jan; 43(1):149-156. PubMed ID: 27987347
[TBL] [Abstract][Full Text] [Related]
12. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
13. Screening of potential biomarkers in uterine leiomyomas disease via gene expression profiling analysis.
Liu X; Liu Y; Zhao J; Liu Y
Mol Med Rep; 2018 May; 17(5):6985-6996. PubMed ID: 29568968
[TBL] [Abstract][Full Text] [Related]
14. MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness.
Gonzalez-Molina J; Hahn P; Falcão RM; Gultekin O; Kokaraki G; Zanfagnin V; Braz Petta T; Lehti K; Carlson JW
Mol Oncol; 2024 Apr; 18(4):850-865. PubMed ID: 37078535
[TBL] [Abstract][Full Text] [Related]
15. Identification of uterine leiomyoma-specific marker genes based on DNA methylation and their clinical application.
Sato S; Maekawa R; Yamagata Y; Tamura I; Lee L; Okada M; Jozaki K; Asada H; Tamura H; Sugino N
Sci Rep; 2016 Aug; 6():30652. PubMed ID: 27498619
[TBL] [Abstract][Full Text] [Related]
16. The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma.
Yang Q; Bariani MV; Falahati A; Khosh A; Lastra RR; Siblini H; Boyer TG; Al-Hendy A
Cells; 2022 Jul; 11(14):. PubMed ID: 35883603
[TBL] [Abstract][Full Text] [Related]
17. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
Rao UN; Finkelstein SD; Jones MW
Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of the DNA methylome and transcriptome in uterine leiomyoma shows altered regulation of genes involved in metabolism, proliferation, extracellular matrix, and vesicles.
Carbajo-García MC; Corachán A; Juárez-Barber E; Monleón J; Payá V; Trelis A; Quiñonero A; Pellicer A; Ferrero H
J Pathol; 2022 Aug; 257(5):663-673. PubMed ID: 35472162
[TBL] [Abstract][Full Text] [Related]
19. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.
Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi D; Sabbatini P; Soslow RA
Int J Gynecol Cancer; 2006; 16(2):849-53. PubMed ID: 16681772
[TBL] [Abstract][Full Text] [Related]
20. MED12 alterations in both human benign and malignant uterine soft tissue tumors.
Pérot G; Croce S; Ribeiro A; Lagarde P; Velasco V; Neuville A; Coindre JM; Stoeckle E; Floquet A; MacGrogan G; Chibon F
PLoS One; 2012; 7(6):e40015. PubMed ID: 22768200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
